Patent · US Active

Antibodies specific to CD44

US12311031B2 · kind B2 · utility

0Cited by

0References

19Claims

0Family size

Assignee

Multitude Inc. · CN

Inventors

Shaofei Zhang · Raleigh, US
Bing Hou · Shanghai, CN
Guangcun Cheng · Shanghai, CN
Shu-Hui Liu · Redwood City, US
Xun Meng · Shanghai, CN

Key dates

Filing date	Jul 27, 2021
Grant date	May 27, 2025
Priority date	—
Expiry date	Oct 17, 2043

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/33
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Antibodies having binding specificity to CD44 v7/8, (a.k.a. CD44 variant 7/8) and antibody-drug conjugates (ADCs) or chimeric antigen receptors comprising such. Also provided herein are uses the anti-CD44 v7/8 antibodies, the ADCs, or immune cells expressing the chimeric antigen receptors for therapeutic and diagnostic purposes.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.